Jennifer Semore, MD
Family Medicine · Oklahoma City, OKNPI 1558523415
Payments from drug & device makers
Across 296 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$791
- Pfizer$594
- AbbVie$507
- AstraZeneca$383
- GSK$354
- Boehringer Ingelheim$317
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,49698%
- Education$732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 57 | $791 |
| Pfizer | 43 | $594 |
| AbbVie(2 entities) | 33 | $507 |
| AstraZeneca | 21 | $383 |
| GSK | 20 | $354 |
| Boehringer Ingelheim | 21 | $317 |
| Novo Nordisk | 16 | $273 |
| Merck | 21 | $263 |
| Astellas Pharma US Inc | 13 | $226 |
| Amgen | 12 | $209 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Exact Sciences | 4 | $63 |
| Nalpropion Pharmaceuticals LLC | 4 | $57 |
| Abbott | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Edwards Lifesciences | 1 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Sobi, Inc | 1 | $26 |
| Shire North American Group Inc | 1 | $21 |
| Gilead | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $15 |
| RARE Disease Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$4,569 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 110 | $127,474 |
| OzempicSemaglutide | 38 | $42,436 |
| EliquisApixaban | 24 | $21,610 |
| MyrbetriqMirabegron | 26 | $21,125 |
| XareltoRivaroxaban | 20 | $15,605 |
| TrulicityDulaglutide | 14 | $13,787 |
| FarxigaDapagliflozin Propanediol | 13 | $13,747 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $13,594 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,260 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $11,093 |
| JanuviaSitagliptin Phosphate | 12 | $7,863 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,618 |
| Atorvastatin Calcium | 236 | $3,757 |
| Omeprazole | 123 | $2,501 |
| FenofibrateFenofibrate Nanocrystallized | 15 | $1,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $791 | $141,261124 claims |
| Novo NordiskOzempic | $273 | $42,43638 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $383 | $26,00730 claims |
| PfizerEliquis | $594 | $21,61024 claims |
| Astellas Pharma US IncMyrbetriq | $226 | $21,12526 claims |
| Boehringer IngelheimSynjardy Xr, Spiriva Respimat | $317 | $18,71126 claims |
| MerckJanuvia | $263 | $7,86312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.